butylhydroxytoluene
Butylated hydroxytoluene (BHT), also known as dibutylhydroxytoluene, is a lipophilic organic compound, chemically a derivative of phenol, that is useful for its antioxidant properties. BHT is widely used to prevent free radical-mediated oxidation in fluids and other materials, and the regulations overseen by the US FDA—which considers BHT to be "generally recognized as safe"—allow small amounts to be added to foods. Despite this, and the earlier determination by the National Cancer Institute that BHT was noncarcinogenic in an animal model, societal concerns over its broad use have been expressed. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2008 (NCT02221375)
Timeline
Indications
Mechanism of action
- Unspecified targetAntioxidant
Antioxidant
Chemistry & pharmacology
SMILES
Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1- Mol. weight
- 220.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaButylated hydroxytoluene ↗
- ChEMBLCHEMBL146 ↗
Also known as
- bht
- bht
- butylated hydroxytoluene
- butylated hydroxytoluene
- butylated hydroxytoluene
- butylhydroxytoluene
- butylhydroxytoluene
- e321
- e321
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03806790 | Phase 3 | Jan 24, 2019 | Leo Pharma |
| NCT02220673 | Phase 1 | Nov 1, 2009 | Boehringer Ingelheim |
| NCT02221375 | Phase 1 | Jun 1, 2008 | Boehringer Ingelheim |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 2 | 1 | 2008 |
| Leo Pharma | For profit | 1 | 1 | 1 | 2019 |